High density lipoprotein future or investigational therapies: Difference between revisions
No edit summary |
|||
| Line 6: | Line 6: | ||
There are promising future therapies that include CETP inhibitors, which are currently in the experimental phase. A combination therapy with [[statins]] and [[ACE inhibitors]] is also a safe option in patients with [[HDL]] levels who also share features with [[dysmetabolic syndrome]]. However, the preventive effects of these two drugs tend to be cumulative.<ref name="pmid12821213">{{cite journal |author=Liem AH, Jukema JW, van Veldhuisen DJ |title=Secondary prevention in coronary heart disease patients with low HDL: which options do we have? |journal=[[International Journal of Cardiology]] |volume=90 |issue=1 |pages=15–21 |year=2003 |month=July |pmid=12821213 |doi= |url=}}</ref> | There are promising future therapies that include CETP inhibitors, which are currently in the experimental phase. A combination therapy with [[statins]] and [[ACE inhibitors]] is also a safe option in patients with [[HDL]] levels who also share features with [[dysmetabolic syndrome]]. However, the preventive effects of these two drugs tend to be cumulative.<ref name="pmid12821213">{{cite journal |author=Liem AH, Jukema JW, van Veldhuisen DJ |title=Secondary prevention in coronary heart disease patients with low HDL: which options do we have? |journal=[[International Journal of Cardiology]] |volume=90 |issue=1 |pages=15–21 |year=2003 |month=July |pmid=12821213 |doi= |url=}}</ref> | ||
==Infusion | ==The Need== | ||
===ApoA-1 Milano=== | ==HDL Infusion/Mimetics== | ||
===CSL-112=== | ===Clinical Significance=== | ||
===CER-001=== | ===Medications=== | ||
====ApoA-1 Milano==== | |||
====CSL-112==== | |||
====CER-001==== | |||
====APP018==== | |||
===Potential Therapeutic Considerations=== | |||
==Cholesterol Ester Transfer Protein (CETP) Inhibition== | ==Cholesterol Ester Transfer Protein (CETP) Inhibition== | ||
| Line 17: | Line 22: | ||
===Evacetrapib=== | ===Evacetrapib=== | ||
==Other Therapies== | ==Other Therapies== | ||
===Endocannabinoid Receptor Blockers=== | ====De-lipidated HDL==== | ||
===JTT-705=== | ====Endocannabinoid Receptor Blockers==== | ||
===CETi-1 Vaccine=== | ====JTT-705==== | ||
====CETi-1 Vaccine==== | |||
====RVX-208==== | |||
==References== | ==References== | ||
Revision as of 14:51, 19 September 2013
|
High Density Lipoprotein Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Clinical Trials |
|
Case Studies |
|
High density lipoprotein future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of High density lipoprotein future or investigational therapies |
|
FDA on High density lipoprotein future or investigational therapies |
|
CDC on High density lipoprotein future or investigational therapies |
|
High density lipoprotein future or investigational therapies in the news |
|
Blogs on High density lipoprotein future or investigational therapies |
|
Risk calculators and risk factors for High density lipoprotein future or investigational therapies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aarti Narayan, M.B.B.S [2]; Raviteja Guddeti, M.B.B.S. [3]
Overview
There are promising future therapies that include CETP inhibitors, which are currently in the experimental phase. A combination therapy with statins and ACE inhibitors is also a safe option in patients with HDL levels who also share features with dysmetabolic syndrome. However, the preventive effects of these two drugs tend to be cumulative.[1]
The Need
HDL Infusion/Mimetics
Clinical Significance
Medications
ApoA-1 Milano
CSL-112
CER-001
APP018
Potential Therapeutic Considerations
Cholesterol Ester Transfer Protein (CETP) Inhibition
Torcetrapib
Dalcetrapib
Anacetrapib
Evacetrapib
Other Therapies
De-lipidated HDL
Endocannabinoid Receptor Blockers
JTT-705
CETi-1 Vaccine
RVX-208
References
- ↑ Liem AH, Jukema JW, van Veldhuisen DJ (2003). "Secondary prevention in coronary heart disease patients with low HDL: which options do we have?". International Journal of Cardiology. 90 (1): 15–21. PMID 12821213. Unknown parameter
|month=ignored (help)